A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

Douglas Kerr Biography and Net Worth

Insider of Generation Bio

Doug served as global development team lead and vice president for neurology at Shire from 2015–2017 where he was responsible for the development of the rare neuroscience programs including the lysosomal storage disorders, neurodegeneration, and gene therapy candidates. Doug served as senior director of corporate strategy and portfolio management at Biogen, where he led the development effort for Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Doug led the development of Spinraza™, now approved for SMA. Doug was on the faculty of The Johns Hopkins School of Medicine as associate professor of neurology with joint appointments in the Department of Molecular Microbiology and Immunology and Cellular and Molecular Medicine, and ran a lab that investigated fundamental aspects of motor neuron/axon biology, provided direct patient care and ran clinical trials, mainly spinal cord and neuromuscular disorders. Doug has participated on the boards and scientific advisory boards of several non-profit organizations, including the Transverse Myelitis Association, CureSMA and the ALS Association. Doug received his medical degree from Jefferson Medical College, as well as his doctorate in biochemistry and molecular biology. Doug obtained his Master of Business Administration, with a specialization in entrepreneurship and finance, as well as his Bachelor of Arts degree in biochemistry from Princeton University.

What is Douglas Kerr's net worth?: The estimated net worth of Douglas Kerr is at least $934,115.08 as of July 8th, 2021. Dr. Kerr owns 330,076 shares of Generation Bio stock worth more than $934,115 as of April 18th. This net worth approximation does not reflect any other investments that Dr. Kerr may own. Learn More about Douglas Kerr's net worth.
How do I contact Douglas Kerr?: The corporate mailing address for Dr. Kerr and other Generation Bio executives is 301 BINNEY STREET, CAMBRIDGE MA, 02142. Generation Bio can also be reached via phone at 617-655-7500 and via email at [email protected]. Learn More on Douglas Kerr's contact information.
Has Douglas Kerr been buying or selling shares of Generation Bio?: Douglas Kerr has not been actively trading shares of Generation Bio during the last ninety days. Most recently, Douglas Kerr sold 3,518 shares of the business's stock in a transaction on Thursday, July 8th. The shares were sold at an average price of $25.20, for a transaction totalling $88,653.60. Following the completion of the sale, the insider now directly owns 330,076 shares of the company's stock, valued at $8,317,915.20. Learn More on Douglas Kerr's trading history.
Who are Generation Bio's active insiders?: Generation Bio's insider roster includes Douglas Kerr (Insider), Geoff McDonough (CEO), Jason Rhodes (Director), Evan Spiegel (CEO), and Matthew Stanton (Insider). Learn More on Generation Bio's active insiders.
Are insiders buying or selling shares of Generation Bio?: In the last twelve months, Generation Bio insiders bought shares 2 times. They purchased a total of 12,637 shares worth more than $19,159.34. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 11,591 shares worth more than $49,239.96. The most recent insider tranaction occured on January, 2nd when COO Antoinette Paone sold 2,445 shares worth more than $3,960.90. Insiders at Generation Bio own 20.8% of the company. Learn More about insider trades at Generation Bio.
Information on this page was last updated on 1/2/2024.

Douglas Kerr Insider Trading History at Generation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/8/2021	Sell	3,518	$25.20	$88,653.60	330,076
4/5/2021	Sell	14,072	$30.09	$423,426.48	340,630
1/11/2021	Sell	11,267	$27.58	$310,743.86	337,825

Douglas Kerr Buying and Selling Activity at Generation Bio

Generation Bio Company Overview

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $2.83

$2.82

$3.08

50 Day Range

MA: $3.02

$1.92

$4.35

2 Week Range

Now: $2.83

$0.86

$6.98

Volume

67,201 shs

Average Volume

272,167 shs

Market Capitalization

$188.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.79

[Urgent!] Generational Wealth Gameplan

From Crypto 101 Media | Ad